FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W968645667> ?p ?o ?g. }

• W968645667 abstract "Context: For patients with relapsed/refractory AML, therapeutic success is unpredictable with current chemotherapeutic regimens. Moreover, multiple courses of therapy have resulted in co-morbid conditions which can preclude the patient from receiving a potentially curative bone marrow transplant. Objective: In order to identify a successful chemotherapeutic regimen for these patients, we have developed a high-throughput assay that utilizes primary (patient-derived) leukemia cells and tested for chemo-sensitivity and resistance against a panel of FDA approved agents used to treat AML. Design: This assay was developed in 1536 well format and optimized against a panel of leukemia and lymphoma cell lines to determine optimal concentration of cells needed to achieve statistically significant reproducible results. Twelve point dose response curves were performed in duplicate for all agents. Alamar Blue reduction and Annexin V staining were used as indicators of cell viability. Results: Using this assay, we demonstrated in vitro resistance against drugs already clinically administered and importantly showed in vitro sensitivity to agents that had not been previously administered. The index patient was a 32-year-old woman with primary refractory AML who had received six different therapeutic regimens prior to testing, all of which demonstrated in vitro resistance using our assay. The blasts were sensitive, however, to 6-thioguanine with an inhibitory concentration (EC50) of 70 nanoM. Based on the in vitro data, she began a combination treatment regimen containing 6-thioguanine. Following a maintenance regimen, her circulating blast count decreased, and she had partial recovery of the neutrophil count, resulting in a dramatic decrease in the overall leukemia burden. This result was not seen with her previous therapies. After over six months of this therapy, her WBC began to rise and repeat testing indicated resistance to 6-thioguanine with EC50 > 10 microM, confirming the response seen in vivo. We have gone on to test samples from more than twenty-five patients with AML and have accurately predicted the in vivo clinical response (both sensitivity and resistance). In the above case, the treatment regimen identified from the screening results is now being tested in a Phase I clinical trial for patients with relapsed/refractory AML or elderly patients unfit to receive standard AML therapy. In other cases, the treatment regimen identified from the screen provided the needed bridge to allogeneic bone marrow transplantation. Conclusions: These data demonstrate that the technology described here to pharmacologically screen drug therapy for patients with relapsed/refractory AML is both clinically useful and has a role in designing individualized treatment regimens for these patients. Citation Format: David Shum, Ruth Santos, Mark Heaney, Renier Brentjens, Peter Maslak, Todd Rosenblat, Joseph Jurcic, Hakim Djaballah, Mark G. Frattini. A novel high-throughput screen of primary leukemia cells to personalize therapy for relapsed/refractory acute myeloid leukemia (AML): Proof of concept and clinical implementation of precision medicine. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy; Jun 18-21, 2014; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(4 Suppl): Abstract nr B10." @default.
• W968645667 created "2016-06-24" @default.
• W968645667 creator A5022479827 @default.
• W968645667 creator A5028207893 @default.
• W968645667 creator A5044188379 @default.
• W968645667 creator A5051627249 @default.
• W968645667 creator A5055703943 @default.
• W968645667 creator A5065556543 @default.
• W968645667 creator A5065970944 @default.
• W968645667 creator A5077735185 @default.
• W968645667 creator A5090616937 @default.
• W968645667 date "2015-02-13" @default.
• W968645667 modified "2023-10-01" @default.
• W968645667 title "Abstract B10: A novel high-throughput screen of primary leukemia cells to personalize therapy for relapsed/refractory acute myeloid leukemia (AML): Proof of concept and clinical implementation of precision medicine" @default.
• W968645667 doi "https://doi.org/10.1158/1557-3265.pms14-b10" @default.
• W968645667 hasPublicationYear "2015" @default.
• W968645667 type Work @default.
• W968645667 sameAs 968645667 @default.
• W968645667 citedByCount "0" @default.
• W968645667 crossrefType "proceedings-article" @default.
• W968645667 hasAuthorship W968645667A5022479827 @default.
• W968645667 hasAuthorship W968645667A5028207893 @default.
• W968645667 hasAuthorship W968645667A5044188379 @default.
• W968645667 hasAuthorship W968645667A5051627249 @default.
• W968645667 hasAuthorship W968645667A5055703943 @default.
• W968645667 hasAuthorship W968645667A5065556543 @default.
• W968645667 hasAuthorship W968645667A5065970944 @default.
• W968645667 hasAuthorship W968645667A5077735185 @default.
• W968645667 hasAuthorship W968645667A5090616937 @default.
• W968645667 hasConcept C126322002 @default.
• W968645667 hasConcept C142424586 @default.
• W968645667 hasConcept C143998085 @default.
• W968645667 hasConcept C151730666 @default.
• W968645667 hasConcept C203014093 @default.
• W968645667 hasConcept C2778041864 @default.
• W968645667 hasConcept C2778461978 @default.
• W968645667 hasConcept C2778729363 @default.
• W968645667 hasConcept C2779343474 @default.
• W968645667 hasConcept C2781413609 @default.
• W968645667 hasConcept C71924100 @default.
• W968645667 hasConcept C86803240 @default.
• W968645667 hasConcept C87355193 @default.
• W968645667 hasConcept C98274493 @default.
• W968645667 hasConceptScore W968645667C126322002 @default.
• W968645667 hasConceptScore W968645667C142424586 @default.
• W968645667 hasConceptScore W968645667C143998085 @default.
• W968645667 hasConceptScore W968645667C151730666 @default.
• W968645667 hasConceptScore W968645667C203014093 @default.
• W968645667 hasConceptScore W968645667C2778041864 @default.
• W968645667 hasConceptScore W968645667C2778461978 @default.
• W968645667 hasConceptScore W968645667C2778729363 @default.
• W968645667 hasConceptScore W968645667C2779343474 @default.
• W968645667 hasConceptScore W968645667C2781413609 @default.
• W968645667 hasConceptScore W968645667C71924100 @default.
• W968645667 hasConceptScore W968645667C86803240 @default.
• W968645667 hasConceptScore W968645667C87355193 @default.
• W968645667 hasConceptScore W968645667C98274493 @default.
• W968645667 hasLocation W9686456671 @default.
• W968645667 hasOpenAccess W968645667 @default.
• W968645667 hasPrimaryLocation W9686456671 @default.
• W968645667 hasRelatedWork W1993233174 @default.
• W968645667 hasRelatedWork W201610554 @default.
• W968645667 hasRelatedWork W2121272861 @default.
• W968645667 hasRelatedWork W2345707195 @default.
• W968645667 hasRelatedWork W2376930159 @default.
• W968645667 hasRelatedWork W2531711809 @default.
• W968645667 hasRelatedWork W2557076948 @default.
• W968645667 hasRelatedWork W2564837373 @default.
• W968645667 hasRelatedWork W2593292925 @default.
• W968645667 hasRelatedWork W2790471571 @default.
• W968645667 hasRelatedWork W2914428531 @default.
• W968645667 hasRelatedWork W2979333870 @default.
• W968645667 hasRelatedWork W2982048065 @default.
• W968645667 hasRelatedWork W3029939358 @default.
• W968645667 hasRelatedWork W3097584833 @default.
• W968645667 hasRelatedWork W3127026655 @default.
• W968645667 hasRelatedWork W3213615512 @default.
• W968645667 hasRelatedWork W747621895 @default.
• W968645667 hasRelatedWork W765180805 @default.
• W968645667 hasRelatedWork W91423968 @default.
• W968645667 isParatext "false" @default.
• W968645667 isRetracted "false" @default.
• W968645667 magId "968645667" @default.
• W968645667 workType "article" @default.